Working... Menu
Trial record 69 of 81 for:    CRVO - Central Retinal Vein Occlusion

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01011374
Recruitment Status : Unknown
Verified March 2011 by Retina Associates of Cleveland, Inc.
Recruitment status was:  Active, not recruiting
First Posted : November 11, 2009
Last Update Posted : March 18, 2011
Genentech, Inc.
Information provided by:
Retina Associates of Cleveland, Inc

Brief Summary:
This is a prospective, single-center, non-randomized clinical study on the impact of intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning and emotional well-being in subjects with central or branch retinal vein occlusion.

Condition or disease Intervention/treatment Phase
Venous Retinal Branch Occlusion Central Retinal Vein Occlusion Retinal Vein Occlusion Depression Drug: ranibizumab (Lucentis) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Impact of Lucentis on Psychological Morbidity in Patients With Macular Edema and Neovascularization Secondary to Retinal Vein Occlusion
Study Start Date : November 2009
Estimated Primary Completion Date : November 2012
Estimated Study Completion Date : November 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab

Intervention Details:
  • Drug: ranibizumab (Lucentis)
    0.5 mg, administered intravitreally every 4 weeks
    Other Name: Lucentis

Primary Outcome Measures :
  1. The primary outcome measures are changes in the VFQ-25, GHQ-12, and PHQ-9 survey scores from baseline through 24 weeks. [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. Secondary outcome measures are change in macular edema measured by OCT and estimated by central retinal thickening and correlations between change in visual acuity, depression, and retinal findings such as neovascularization, rubeosis, and perfusion. [ Time Frame: 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Evidence of central retinal vein occlusion, defined as documented retinal hemorrhage into all four quadrants with dilated veins, or branch retinal vein occlusion, as documented on clinical exam
  • Age 18 years or over
  • Central macular edema on clinical exam as well as imaging with a central thickness of ≥ 250 microns
  • Visual acuity ranging from 20/8000 to 20/40
  • Media clarity and patient cooperation sufficient to allow adequate testing utilizing OCT and FA
  • No previous treatment that might compromise or confound assessment of the study outcomes
  • Ability to speak and read English

Exclusion Criteria:

  • Acute illness or cognitive or other impairment that, in the opinion of the investigator, would interfere with study requirements
  • Concurrent ocular conditions likely to significantly compromise vision and contribute the macular compromise
  • History of grid/focal laser in the study eye
  • History of vitreal surgery
  • Previous treatment with triamcinolone acetonide in either eye
  • Previous use of bevacizumab, pegaptanib, or ranibizumab in either eye
  • Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders
  • History of cerebrovascular accident within 1 year prior to Day 0
  • Inability to comply with study or follow-up procedures
  • Any cognitive defect as a result of mental disease, previous injury, or disease process that may interfere with interpretation of study results
  • Visual acuity better than 20/40
  • Pregnancy (positive pregnancy test) or lactation
  • Inadequate contraception in premenopausal women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01011374

Layout table for location information
United States, Ohio
Retina Associates of Cleveland
Cleveland, Ohio, United States, 44122
Sponsors and Collaborators
Retina Associates of Cleveland, Inc
Genentech, Inc.
Layout table for investigator information
Principal Investigator: Lawrence J Singerman, MD Retina Associates of Cleveland

Layout table for additonal information
Responsible Party: Lawrence J. Singerman, MD, Retina Associates of Cleveland Identifier: NCT01011374     History of Changes
Other Study ID Numbers: FVF4638s
First Posted: November 11, 2009    Key Record Dates
Last Update Posted: March 18, 2011
Last Verified: March 2011

Keywords provided by Retina Associates of Cleveland, Inc:
Retinal vein occlusion

Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Vein Occlusion
Retinal Diseases
Venous Thrombosis
Behavioral Symptoms
Eye Diseases
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents